Europe Overactive Bladder Treatment Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive Bladder

Europe Overactive Bladder Treatment Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive Bladder and Neurogenic Bladder)

The Europe overactive bladder treatment market is expected to grow from US$ 1,111.05 million in 2022 to US$ 1,318.55 million by 2028; it is estimated to grow at a CAGR of 2.9% from 2022 to 2028.

Growing Incidence of Urinary Tract Infections Fuels Europe Overactive Bladder Treatment Market Growth

Urinary tract infection (UTI) may lead to increased activity in the bladder wall muscles, causing symptoms similar to an overactive bladder. The bacteria causing UTIs reside in the lining of urothelial cells, and they attack the host body when their innate immunity is low. Individuals with recurrent UTIs are found to have voiding dysfunction and detrusor overactivity, and these functional abnormalities can further damage the integrity of the urothelial barrier. UTI is the eighth and fifth most common reason for ambulatory clinic visits and emergency department visits, respectively, in the country. Moreover, as per the National Institute for Health and Care Excellence organization, UTIs are among the most common hospital-acquired infections in the UK, accounting for ~23% of all infections. According to the BMC Family Practice, UTI consultations accounted for ~2% of ED visits in the Netherlands in 2019. Similarly, in France, ~4–6 million people suffer from UTI each year. Thus, the increasing incidence of UTIs, coupled with the association of UTIs with overactive bladder, is one of the prominent factors contributing to the Europe overactive bladder treatment market growth.

Europe Overactive Bladder Treatment Market Overview

The Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global overactive bladder treatment market and is estimated to register a substantial CAGR over the forecast period. The growing demand for overactive bladder treatment due to the presence of the geriatric population is driving the market growth in Europe. Further, the prevalence of neurological diseases and diabetes hampering urinary tract functions is likely to create opportunities for the growth of overactive bladder treatment in the coming years. According to the UK Parliament’s data, approximately one-fifth of the total UK population was aged 65 and above in 2019. Besides, the number of people in this age group increased by 23% from 2009 to 2019, while the total UK population increased by only 7% during the same period. Diabetes UK states that ~3.9 million people were diagnosed with diabetes in 2019, and it reached 4.7 million in 2021. The rising prevalence of diabetes and the growing elderly population in the UK lead to surging cases of overactive bladder condition, thereby stroking the demand for its treatment.

Europe Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)

Europe Overactive Bladder Treatment Market Segmentation

The Europe overactive bladder treatment market is segmented into pharmacotherapy, disease type, and country.

The Europe overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.

Based on pharmacotherapy, the market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022. Based on disease type, the Europe overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022. Based on country, the Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK dominated the market in 2022. AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the overactive bladder treatment market in Europe.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe overactive bladder treatment market
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe overactive bladder treatment market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the overactive bladder treatment market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution